What Is Efocipegtrutide (HM15211)? The Triple GLP-1/GIP/Glucagon Peptide Being Studied for MASH

The next generation of metabolic peptides is increasingly moving beyond single- and dual-receptor agonists.

Efocipegtrutide, previously known as HM15211, is one of the more unusual examples.

It is a long-acting experimental peptide designed to activate three metabolic hormone receptors simultaneously:

• GLP-1
• GIP
• glucagon

But unlike several triple agonists being developed primarily for obesity, efocipegtrutide has been engineered with a particular focus on the liver.

Its main clinical programme has investigated whether triple-receptor signalling can simultaneously address the three major components of metabolic dysfunction-associated steatohepatitis, or MASH:

fat accumulation, inflammation and fibrosis.

What Is Efocipegtrutide?

Efocipegtrutide is an investigational once-weekly peptide developed by Hanmi Pharmaceutical.

It is also known by its earlier development name:

HM15211

The molecule combines agonist activity at:

glucagon + GIP + GLP-1 receptors.

Hanmi describes the compound as having been designed to provide enhanced liver exposure and multiple metabolic effects relevant to MASH. (hanmi.co.kr⁠)

Why Target Three Receptors?

Each receptor contributes something different.

GLP-1

GLP-1 signalling can influence:

• appetite
• satiety
• insulin secretion
• glucose regulation
• body weight

GIP

GIP is another incretin hormone involved in:

• insulin secretion
• nutrient handling
• adipose-tissue metabolism

Glucagon

Glucagon is particularly interesting in liver research.

Its signalling can influence:

• hepatic lipid metabolism
• fatty-acid oxidation
• energy expenditure
• glucose production

Combining all three potentially creates a broader metabolic effect than targeting GLP-1 alone.

Why Is the Glucagon Component Important for MASH?

MASH involves excessive fat accumulation within the liver together with inflammation and, in some people, progressive fibrosis.

Weight reduction can improve liver health.

But researchers are also interested in drugs that influence the liver more directly.

Glucagon receptor activation can promote fat oxidation within the liver, giving triple agonists a potential mechanism beyond appetite suppression alone.

That is one reason efocipegtrutide was designed specifically around liver disease rather than simply obesity.

What Is MASH?

MASH stands for metabolic dysfunction-associated steatohepatitis.

It was previously commonly called NASH.

The condition develops when metabolic liver fat is accompanied by inflammation and cellular injury.

Over time, this can lead to:

• liver fibrosis
• cirrhosis
• liver failure
• hepatocellular carcinoma
• cardiovascular complications

The severity of fibrosis is particularly important because advanced fibrosis is strongly associated with long-term liver outcomes.

How Might Efocipegtrutide Affect Liver Fat?

Earlier Phase 1b/2a research investigated efocipegtrutide in people with obesity and fatty liver disease.

Sixty participants were treated for approximately 12 weeks.

Hanmi reported dose-dependent reductions in liver fat measured by MRI-PDFF.

Relative liver-fat reductions ranged from approximately:

• 19.6% at 0.01 mg/kg
• 43.0% at 0.02 mg/kg
• 44.5% at 0.04 mg/kg
• 71.0% at 0.06 mg/kg
• 81.1% at 0.08 mg/kg

compared with approximately 5.7% with placebo. (hanmi.co.kr⁠)

These were early-stage results, but they provided the basis for larger MASH trials.

Why Is an 80% Reduction in Liver Fat Interesting?

MRI-PDFF allows researchers to quantify the percentage of fat contained within liver tissue.

A large reduction suggests that the metabolic environment within the liver has changed substantially.

However, reducing liver fat is only part of treating MASH.

A treatment also needs to demonstrate meaningful effects on:

• inflammation
• liver-cell injury
• fibrosis

That is why later studies use liver biopsy and fibrosis endpoints rather than relying only on MRI measurements.

What Was the HM-TRIA-201 Trial?

Efocipegtrutide progressed into a larger Phase 2 clinical trial called HM-TRIA-201.

The study was designed as a:

• multicentre
• randomised
• double-blind
• placebo-controlled
• 52-week trial

in people with biopsy-confirmed MASH. (PubMed⁠)

The ClinicalTrials.gov record lists 215 participants actually enrolled. (ClinicalTrials⁠)

What Doses Were Tested?

Participants were assigned to receive:

• placebo
• 2 mg efocipegtrutide
• 4 mg efocipegtrutide
• 6 mg efocipegtrutide

The treatment period lasted approximately one year.

The study focused specifically on people with liver fibrosis associated with MASH.

What Was the Main Endpoint?

One of the principal goals was to determine whether efocipegtrutide could produce:

resolution of steatohepatitis without worsening liver fibrosis.

This is much more clinically meaningful than simply demonstrating reduced liver fat.

It asks whether the underlying inflammatory liver disease itself has improved.

Has the Phase 2 Trial Finished?

According to the most recent ClinicalTrials.gov record, the study was active but no longer recruiting, with estimated primary completion in June 2026 and overall completion in July 2026. (ClinicalTrials⁠)

As of October 2026, however, the trial registry does not yet contain posted results.

That distinction is important.

The study reaching completion does not mean we can assume that its primary endpoint was successful.

The detailed Phase 2b findings still need to be publicly reported and evaluated.

Has Efocipegtrutide Received FDA Fast Track Status?

Yes.

The FDA previously granted efocipegtrutide Fast Track designation for MASH/NASH development.

Fast Track designation is intended to facilitate development of treatments for serious conditions with unmet medical needs.

It does not mean the drug has been approved or proven effective. (hanmi.co.kr⁠)

Is Efocipegtrutide Only Being Studied for MASH?

No.

Hanmi has explored the compound’s potential in several fibrotic diseases.

The company reports orphan-drug designations relating to conditions including:

• idiopathic pulmonary fibrosis
• primary biliary cholangitis
• primary sclerosing cholangitis

These indications reflect interest in whether the molecule’s metabolic and anti-fibrotic effects could extend beyond fatty liver disease. (hanmi.co.kr⁠)

Why Would a Metabolic Peptide Affect Fibrosis?

Fibrosis is the excessive accumulation of scar-like extracellular matrix within tissue.

In MASH, chronic metabolic stress can lead to:

fat accumulation

↓

cellular injury

↓

inflammation

↓

activation of hepatic stellate cells

↓

fibrosis

Efocipegtrutide is being investigated because its combined receptor effects may influence several points within this chain rather than acting on only one process.

Hanmi describes the molecule as being designed to address steatosis, inflammation and fibrosis simultaneously. (hanmi.co.kr⁠)

How Is Efocipegtrutide Different From Retatrutide?

Both compounds target:

• GLP-1
• GIP
• glucagon

But they are different molecules designed with different priorities.

Retatrutide has received considerable attention for obesity and weight reduction.

Efocipegtrutide has been developed primarily around liver disease and MASH.

Their receptor balance, pharmacokinetics and tissue distribution also differ.

Triple agonism therefore describes a broad strategy rather than one identical type of drug.

How Is Efocipegtrutide Different From Pemvidutide?

Pemvidutide targets:

GLP-1 + glucagon

Efocipegtrutide targets:

GLP-1 + GIP + glucagon

Efocipegtrutide therefore adds GIP receptor activity.

Both are being studied in MASH, but their receptor architecture is different.

How Is It Different From Survodutide?

Survodutide also targets:

GLP-1 + glucagon

Efocipegtrutide again adds the third GIP pathway.

Whether that additional receptor activity provides meaningful advantages for liver disease remains an open clinical question.

Are Triple Agonists Automatically Better?

No.

Adding receptors can increase biological complexity.

A triple agonist has to achieve an appropriate balance between three different hormonal signals.

Too much activity at one receptor could potentially reduce tolerability or create unwanted metabolic effects.

The quality of the receptor balance therefore matters more than simply counting how many receptors a molecule activates.

What Are the Potential Safety Issues?

As with other incretin-based peptides, gastrointestinal adverse effects such as:

• nausea
• vomiting
• diarrhoea

are important considerations.

Glucagon receptor activation also requires careful monitoring because glucagon can increase blood glucose under some circumstances.

Researchers therefore need to determine whether the GLP-1 and GIP components sufficiently counterbalance this effect while preserving the potential liver benefits of glucagon signalling.

Is Efocipegtrutide a Peptide?

Yes.

Efocipegtrutide is a long-acting peptide triple receptor agonist.

It uses Hanmi’s long-acting LAPSCOVERY platform to allow approximately once-weekly administration. (hanmi.co.kr⁠)

Is Efocipegtrutide Approved?

No.

Efocipegtrutide remains investigational.

Although the Phase 2b trial has reached its planned completion period, detailed results have not yet been posted to the trial registry.

There is therefore currently no basis for treating it as an established MASH therapy. (ClinicalTrials⁠)

Why Is Efocipegtrutide Worth Watching?

Most metabolic peptide development begins with one obvious objective:

reduce body weight.

Efocipegtrutide represents a different strategy.

Its development asks whether the same metabolic hormone pathways can be deliberately engineered to target an organ-specific disease.

The liver provides an ideal test case because GLP-1, GIP and glucagon signalling intersect with:

• energy balance
• insulin resistance
• lipid metabolism
• inflammation
• hepatic fat
• fibrosis

That makes efocipegtrutide more than another weight-loss peptide.

The Bottom Line

Efocipegtrutide, previously known as HM15211, is an investigational once-weekly GLP-1/GIP/glucagon triple receptor agonist developed primarily for MASH.

Earlier clinical research reported dose-dependent reductions in liver fat, reaching approximately 81% relative reduction after 12 weeks at the highest studied dose. (hanmi.co.kr⁠)

Those findings led to the larger HM-TRIA-201 Phase 2 study involving 215 participants with biopsy-confirmed MASH. (ClinicalTrials⁠)

As of October 2026, that trial has reached its scheduled completion period, but detailed clinical results have not yet been posted publicly.

That means the most important question remains unanswered:

Can the dramatic reductions in liver fat translate into meaningful improvements in MASH and fibrosis?

If the Phase 2b biopsy results eventually demonstrate that, efocipegtrutide could become one of the more scientifically important applications of triple-receptor peptide therapy outside conventional obesity treatment.

This article is for research and educational purposes only. Efocipegtrutide remains investigational and is not presented as an approved treatment.